NO20052855D0 - Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav. - Google Patents

Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.

Info

Publication number: NO20052855D0
Authority: NO; Norway
Prior art keywords: phosphonoxycinazoline; derivatives; pharmaceutical use; pharmaceutical; phosphonoxycinazoline derivatives
Prior art date: 2002-12-24

Application number

NO20052855A

Other languages

English (en)

Other versions

NO335193B1 (no

NO20052855L (no

Inventor

Frederic Henri Jung

Andrew Austen Mortlock

Georges Rene Pasquet

Nicola Murdoch Heron

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-24

Filing date

2005-06-13

Publication date

2005-06-13

2005-06-13 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-06-13 Publication of NO20052855D0 publication Critical patent/NO20052855D0/no

2005-08-03 Publication of NO20052855L publication Critical patent/NO20052855L/no

2014-10-20 Publication of NO335193B1 publication Critical patent/NO335193B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20052855A 2002-12-24 2005-06-13 Fosfonoksykinazolinderivater, farmasøytisk preparat omfattende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom NO335193B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02293238		2002-12-24
EP03291315		2003-06-02
PCT/GB2003/005613 WO2004058781A1 (en)	2002-12-24	2003-12-22	Phosphonooxy quinazoline derivatives and their pharmaceutical use

Publications (3)

Publication Number	Publication Date
NO20052855D0 true NO20052855D0 (no)	2005-06-13
NO20052855L NO20052855L (no)	2005-08-03
NO335193B1 NO335193B1 (no)	2014-10-20

Family

ID=32683824

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20052855A NO335193B1 (no)	2002-12-24	2005-06-13	Fosfonoksykinazolinderivater, farmasøytisk preparat omfattende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom
NO20131444A NO335446B1 (no)	2002-12-24	2013-11-01	Kinazolinderivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20131444A NO335446B1 (no)	2002-12-24	2013-11-01	Kinazolinderivater

Country Status (30)

Country	Link
US (4)	US7528121B2 (no)
EP (2)	EP1847539B1 (no)
JP (3)	JP4422102B2 (no)
KR (1)	KR101010299B1 (no)
AR (2)	AR042668A1 (no)
AT (2)	ATE370958T1 (no)
AU (1)	AU2003290313B2 (no)
BR (1)	BRPI0317717B8 (no)
CA (1)	CA2511613C (no)
CL (1)	CL2003002731A1 (no)
CY (2)	CY1107775T1 (no)
DE (2)	DE60328735D1 (no)
DK (2)	DK1847539T3 (no)
ES (2)	ES2329623T3 (no)
HK (2)	HK1080481A1 (no)
IL (2)	IL169112A (no)
IS (2)	IS2504B (no)
MX (1)	MXPA05006918A (no)
MY (2)	MY136174A (no)
NO (2)	NO335193B1 (no)
NZ (1)	NZ540698A (no)
PL (2)	PL223998B1 (no)
PT (2)	PT1847539E (no)
RU (3)	RU2357971C2 (no)
SA (1)	SA04240504B1 (no)
SI (2)	SI1578755T1 (no)
TW (2)	TWI336327B (no)
UA (1)	UA83814C2 (no)
UY (1)	UY28149A1 (no)
WO (1)	WO2004058781A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100491372C (zh) *	2001-12-24	2009-05-27	阿斯特拉曾尼卡有限公司	作为欧若拉激酶抑制剂的取代喹唑啉衍生物
CA2508921A1 (en) *	2002-12-24	2004-07-15	Astrazeneca Ab	Quinazoline compounds
RU2357971C2 (ru)	2002-12-24	2009-06-10	Астразенека Аб	Производные фосфонооксихиназолина и их фармацевтическое применение
CN1809557B (zh) *	2003-04-16	2012-07-04	阿斯利康(瑞典)有限公司	化合物
EP2251343A1 (en) *	2003-05-15	2010-11-17	Arqule, Inc.	Imidazothiazoles as p38-kinase-inhibitors
WO2004105764A1 (en) *	2003-06-02	2004-12-09	Astrazeneca Ab	(3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
CN101072758B (zh) *	2004-10-12	2013-07-31	阿斯利康(瑞典)有限公司	喹唑啉衍生物
WO2006040526A1 (en) *	2004-10-12	2006-04-20	Astrazeneca Ab	Quinazoline derivatives for use against cancer
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2006044869A1 (en) *	2004-10-19	2006-04-27	Arqule, Inc.	Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
UY30183A1 (es)	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
US7501430B2 (en) *	2006-04-17	2009-03-10	Arqule, Inc.	RAF inhibitors and their uses
GB0609617D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
GB0609621D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
GB0609619D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Combination
JP2010505962A (ja)	2006-10-09	2010-02-25	武田薬品工業株式会社	キナーゼ阻害剤
WO2009111028A1 (en) *	2008-03-04	2009-09-11	Vitae Pharmaceuticals, Inc.	Aurora kinase inhibitors
WO2009114703A2 (en) *	2008-03-12	2009-09-17	Fox Chase Cancer Center	Combination therapy for the treatment of cancer
JP5502072B2 (ja)	2008-04-30	2014-05-28	ナショナルヘルスリサーチインスティテューツ	オーロラキナーゼ阻害剤としての縮合二環式ピリミジン化合物
AU2009267161B2 (en) *	2008-07-03	2014-11-06	Merck Patent Gmbh	Naphthyridininones as Aurora kinase inhibitors
AU2009322158A1 (en) *	2008-12-05	2010-06-10	Arqule, Inc.	RAF inhibitors and their uses
US7863325B2 (en)	2008-12-11	2011-01-04	Axcentua Pharmaceuticals Ab	Crystalline genistein sodium salt dihydrate
CA2746652C (en)	2008-12-11	2018-03-06	Axcentua Pharmaceuticals Ab	Crystalline forms of genistein
CN102264368B (zh)	2008-12-22	2014-09-10	米伦纽姆医药公司	极光激酶抑制剂与抗cd20抗体的组合
ES2609578T3 (es)	2011-03-04	2017-04-21	Glaxosmithkline Intellectual Property Development Limited	Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh)	2012-09-13	2014-07-01	Glaxosmithkline Llc	作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CA2900652C (en)	2013-02-15	2021-05-04	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en)	2013-02-20	2016-05-31	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
TWI630203B (zh) *	2013-02-21	2018-07-21	葛蘭素史克智慧財產發展有限公司	做為激酶抑制劑的喹唑啉類
SI3311845T1 (sl) *	2013-09-16	2020-06-30	Astrazeneca Ab	Terapevtski polimerni nanodelci in postopki njihove izdelave in uporabe
EP3062618B1 (en)	2013-11-01	2020-02-05	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
JP6525474B2 (ja)	2013-12-06	2019-06-05	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP2018524292A (ja)	2015-07-21	2018-08-30	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	オーロラキナーゼインヒビターと化学療法剤の投与
WO2018048750A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en)	2016-09-08	2019-04-09	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en)	2016-09-08	2020-05-20	Kala Pharmaceuticals, Inc.	CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
SG11202001728YA (en)	2017-09-08	2020-03-30	Univ Leland Stanford Junior	Enpp1 inhibitors and their use for the treatment of cancer
WO2019195658A1 (en)	2018-04-05	2019-10-10	Dana-Farber Cancer Institute, Inc.	Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es)	2018-09-09	2020-03-12	Fundacio Privada Institut De Recerca De La Sida - Caixa	Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en)	2019-08-26	2021-03-04	Dana-Farber Cancer Institute, Inc.	Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) *	2019-12-11	2022-05-17	苏州美诺医药科技有限公司	新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en)	2021-03-10	2022-09-15	Astrazeneca Ab	Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2102780C (en)	1991-05-10	2007-01-09	Alfred P. Spada	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
WO1995033724A1 (en)	1994-06-09	1995-12-14	Glaxo Group Limited	Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (no)	1994-11-12	1997-12-01	Zeneca Ltd
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
US6716575B2 (en)	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
KR100459052B1 (ko)	1995-12-18	2005-01-15	서젠, 인크.	Aur-1및(또는)aur-2관련질병의진단및치료
CA2242425C (en)	1996-02-13	2006-07-18	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
CA2244897C (en)	1996-03-05	2006-04-11	Zeneca Limited	4-anilinoquinazoline derivatives
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
JP2002527436A (ja)	1998-10-08	2002-08-27	アストラゼネカアクチボラグ	キナゾリン誘導体
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
CA2384291A1 (en)	1999-09-21	2001-03-29	Astrazeneca Ab	Quinazoline derivatives and their use as pharmaceuticals
JP2003535078A (ja)	2000-05-31	2003-11-25	アストラゼネカアクチボラグ	血管損傷活性のあるインドール誘導体
US6919338B2 (en)	2000-06-28	2005-07-19	Astrazeneca Ab	Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
HUP0301742A3 (en)	2000-07-07	2005-08-29	Angiogene Pharm Ltd	Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
CA2411160A1 (en)	2000-07-07	2002-01-17	Angiogene Pharmaceuticals Limited	Colchinol derivatives as vascular damaging agents
US6610677B2 (en)	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
AU2002350105A1 (en)	2001-06-21	2003-01-08	Ariad Pharmaceuticals, Inc.	Novel quinazolines and uses thereof
GB0124299D0 (en) *	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
CN100491372C (zh) *	2001-12-24	2009-05-27	阿斯特拉曾尼卡有限公司	作为欧若拉激酶抑制剂的取代喹唑啉衍生物
RU2357971C2 (ru) *	2002-12-24	2009-06-10	Астразенека Аб	Производные фосфонооксихиназолина и их фармацевтическое применение
CA2508921A1 (en) *	2002-12-24	2004-07-15	Astrazeneca Ab	Quinazoline compounds
CN1809557B (zh) *	2003-04-16	2012-07-04	阿斯利康(瑞典)有限公司	化合物

2003
- 2003-12-22 RU RU2005123485/04A patent/RU2357971C2/ru active
- 2003-12-22 AT AT03782672T patent/ATE370958T1/de active
- 2003-12-22 PT PT07009390T patent/PT1847539E/pt unknown
- 2003-12-22 EP EP07009390A patent/EP1847539B1/en not_active Expired - Lifetime
- 2003-12-22 ES ES07009390T patent/ES2329623T3/es not_active Expired - Lifetime
- 2003-12-22 RU RU2007121850/04A patent/RU2350611C1/ru active
- 2003-12-22 MX MXPA05006918A patent/MXPA05006918A/es active IP Right Grant
- 2003-12-22 JP JP2005509716A patent/JP4422102B2/ja not_active Expired - Lifetime
- 2003-12-22 DE DE60328735T patent/DE60328735D1/de not_active Expired - Lifetime
- 2003-12-22 ES ES03782672T patent/ES2290529T3/es not_active Expired - Lifetime
- 2003-12-22 SI SI200330965T patent/SI1578755T1/sl unknown
- 2003-12-22 SI SI200331673T patent/SI1847539T1/sl unknown
- 2003-12-22 AT AT07009390T patent/ATE438644T1/de active
- 2003-12-22 CA CA2511613A patent/CA2511613C/en not_active Expired - Lifetime
- 2003-12-22 MY MYPI20034944A patent/MY136174A/en unknown
- 2003-12-22 BR BRPI0317717A patent/BRPI0317717B8/pt not_active IP Right Cessation
- 2003-12-22 AU AU2003290313A patent/AU2003290313B2/en not_active Expired
- 2003-12-22 CL CL200302731A patent/CL2003002731A1/es unknown
- 2003-12-22 PL PL412704A patent/PL223998B1/pl unknown
- 2003-12-22 US US10/539,220 patent/US7528121B2/en active Active
- 2003-12-22 DE DE60315892T patent/DE60315892T2/de not_active Expired - Lifetime
- 2003-12-22 DK DK07009390T patent/DK1847539T3/da active
- 2003-12-22 UA UAA200507294A patent/UA83814C2/ru unknown
- 2003-12-22 EP EP03782672A patent/EP1578755B1/en not_active Expired - Lifetime
- 2003-12-22 MY MYPI20071321A patent/MY147761A/en unknown
- 2003-12-22 KR KR1020057012015A patent/KR101010299B1/ko active IP Right Grant
- 2003-12-22 PL PL377680A patent/PL221490B1/pl unknown
- 2003-12-22 PT PT03782672T patent/PT1578755E/pt unknown
- 2003-12-22 NZ NZ540698A patent/NZ540698A/en not_active IP Right Cessation
- 2003-12-22 DK DK03782672T patent/DK1578755T3/da active
- 2003-12-22 WO PCT/GB2003/005613 patent/WO2004058781A1/en active Application Filing
- 2003-12-23 UY UY28149A patent/UY28149A1/es not_active Application Discontinuation
- 2003-12-23 TW TW092136601A patent/TWI336327B/zh not_active IP Right Cessation
- 2003-12-23 AR ARP030104824A patent/AR042668A1/es active IP Right Grant
- 2003-12-23 TW TW099134275A patent/TWI393710B/zh not_active IP Right Cessation
2004
- 2004-02-18 SA SA04240504A patent/SA04240504B1/ar unknown
2005
- 2005-06-09 IL IL169112A patent/IL169112A/en active IP Right Grant
- 2005-06-13 NO NO20052855A patent/NO335193B1/no not_active IP Right Cessation
- 2005-07-20 IS IS7948A patent/IS2504B/is unknown
2006
- 2006-01-10 HK HK06100400A patent/HK1080481A1/xx not_active IP Right Cessation
2007
- 2007-05-16 AR ARP070102117A patent/AR057753A2/es not_active Application Discontinuation
- 2007-06-13 RU RU2007121850/04K patent/RU2007121850A/ru unknown
- 2007-06-28 JP JP2007169891A patent/JP4906608B2/ja not_active Expired - Lifetime
- 2007-08-09 IL IL185176A patent/IL185176A/en active IP Right Grant
- 2007-10-24 CY CY20071101369T patent/CY1107775T1/el unknown
2008
- 2008-02-13 IS IS8714A patent/IS2884B/is unknown
- 2008-02-27 HK HK08102177.3A patent/HK1111417A1/xx not_active IP Right Cessation
- 2008-10-15 JP JP2008265949A patent/JP4503090B2/ja not_active Expired - Lifetime
2009
- 2009-04-28 US US12/431,165 patent/US8268841B2/en active Active
- 2009-10-13 CY CY20091101054T patent/CY1109479T1/el unknown
2012
- 2012-08-21 US US13/590,662 patent/US9018191B2/en not_active Expired - Lifetime
2013
- 2013-11-01 NO NO20131444A patent/NO335446B1/no not_active IP Right Cessation
2015
- 2015-03-18 US US14/661,657 patent/US9567358B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CY1107775T1 (el)	2013-06-19
SI1578755T1 (sl)	2007-12-31
HK1111417A1 (en)	2008-08-08
IL185176A (en)	2011-10-31
DE60315892T2 (de)	2008-08-14
JP2006512418A (ja)	2006-04-13
IL169112A (en)	2010-12-30
US9018191B2 (en)	2015-04-28
NO335446B1 (no)	2014-12-15
UY28149A1 (es)	2004-07-30
BRPI0317717B8 (pt)	2021-05-25
IS8714A (is)	2008-02-13
US20150307534A1 (en)	2015-10-29
NO335193B1 (no)	2014-10-20
JP4503090B2 (ja)	2010-07-14
IS2504B (is)	2009-04-15
EP1847539B1 (en)	2009-08-05
KR101010299B1 (ko)	2011-01-25
DE60328735D1 (de)	2009-09-17
EP1578755B1 (en)	2007-08-22
EP1578755A1 (en)	2005-09-28
PT1578755E (pt)	2007-10-19
ES2290529T3 (es)	2008-02-16
SI1847539T1 (sl)	2010-01-29
US20060116357A1 (en)	2006-06-01
PT1847539E (pt)	2009-10-06
MY136174A (en)	2008-08-29
AU2003290313B2 (en)	2007-05-10
BR0317717A (pt)	2005-11-22
TWI393710B (zh)	2013-04-21
BRPI0317717B1 (pt)	2017-12-19
ATE370958T1 (de)	2007-09-15
WO2004058781A1 (en)	2004-07-15
PL223998B1 (pl)	2016-11-30
CY1109479T1 (el)	2014-08-13
ES2329623T3 (es)	2009-11-27
IL169112A0 (en)	2009-02-11
RU2350611C1 (ru)	2009-03-27
HK1080481A1 (en)	2006-04-28
JP2009046514A (ja)	2009-03-05
EP1847539A1 (en)	2007-10-24
PL377680A1 (pl)	2006-02-06
TW200510342A (en)	2005-03-16
DK1578755T3 (da)	2007-11-12
JP4906608B2 (ja)	2012-03-28
UA83814C2 (ru)	2008-08-26
TW201102369A (en)	2011-01-16
RU2007121850A (ru)	2008-12-20
US20140162984A1 (en)	2014-06-12
JP4422102B2 (ja)	2010-02-24
US8268841B2 (en)	2012-09-18
NO20131444L (no)	2005-08-03
CA2511613C (en)	2012-10-02
NZ540698A (en)	2008-05-30
IS7948A (is)	2005-07-20
MY147761A (en)	2013-01-31
US20100069412A1 (en)	2010-03-18
PL412704A1 (pl)	2015-10-12
PL221490B1 (pl)	2016-04-29
SA04240504A (ar)	2005-12-03
IL185176A0 (en)	2007-12-03
KR20050088333A (ko)	2005-09-05
JP2007326862A (ja)	2007-12-20
MXPA05006918A (es)	2005-08-18
TWI336327B (en)	2011-01-21
ATE438644T1 (de)	2009-08-15
US9567358B2 (en)	2017-02-14
SA04240504B1 (ar)	2008-04-01
DK1847539T3 (da)	2009-11-09
AR042668A1 (es)	2005-06-29
AR057753A2 (es)	2007-12-19
RU2357971C2 (ru)	2009-06-10
AU2003290313A1 (en)	2004-07-22
IS2884B (is)	2014-06-15
US7528121B2 (en)	2009-05-05
CA2511613A1 (en)	2004-07-15
CL2003002731A1 (es)	2005-01-07
DE60315892D1 (de)	2007-10-04
NO20052855L (no)	2005-08-03
RU2005123485A (ru)	2006-03-10

Publication	Publication Date	Title
NO20052855D0 (no)	2005-06-13	Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
IS2599B (is)	2010-04-15	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
NO20053974D0 (no)	2005-08-25	Tienopyrimidinforbindelser og anvendelse derav.
NO20052524D0 (no)	2005-05-26	Aminerte isofiavonoidderivater og anvendelse derav
NO20043733L (no)	2004-10-20	Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme
DK1400518T3 (da)	2007-03-26	Heterocycliske forbindelser og lægemidler
IS3007B (is)	2018-12-15	Ónæmisbælandi efnasambönd og efnablöndur
DK1673349T3 (da)	2010-10-25	Benzimidazolderivater: fremstilling og farmaceutiske anvendelser
NO20053817D0 (no)	2005-08-12	Preparater og fremgangsmater for antiviral kombinasjonsterapi.
DK1575618T3 (da)	2006-11-13	Dispergerbare farmaceutiske kombinationer
IS8146A (is)	2005-11-24	Setnar 3-alkýl og 3-alkenýl asetidín afleiður
DK1641822T3 (da)	2013-07-22	Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
NO20053356L (no)	2005-07-11	Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20055568D0 (no)	2005-11-24	Substituerte 1,4-diazepiner og anvendelser derav
EE200300311A (et)	2003-10-15	Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
IS7594A (is)	2004-12-13	Laxófoxifen tafla og húðun hennar
DK1511734T3 (da)	2010-08-02	Forbindelser, præparater og fremgangsmåder
DK1513836T3 (da)	2006-09-11	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da)	2010-08-09	Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1387838T3 (da)	2006-08-14	Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20043333L (no)	2004-09-13	Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
DK1525193T3 (da)	2008-04-28	Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
NO20054135D0 (no)	2005-09-06	Kipolinon/benzoksazin derivater og anvendelser derav
NO20051983D0 (no)	2005-04-22	3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
IS7798A (is)	2005-04-11	Efnasambönd, lyfjablöndur og aðferðir

Legal Events

Date	Code	Title	Description
2024-01-15	MK1K	Patent expired